<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00846703</url>
  </required_header>
  <id_info>
    <org_study_id>2007016</org_study_id>
    <nct_id>NCT00846703</nct_id>
  </id_info>
  <brief_title>The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Guangdong work group of childhood acute lymphoblastic leukemia (ALL) therapy was set up
      in October 2002. The investigators treated the childhood ALL with a GZ2002 protocol since the
      year 2002, and the protocol was mainly derived from the ALLIC-BFM 2002 protocol. After
      summarizing the last six years' experience, our group revised the GZ2002 ALL protocol in the
      year 2008, which is named GD-2008 ALL protocol. The diagnosis and classified criteria is
      according to the ALLIC-BFM 2002 protocol, and the chemotherapy protocol consists all the
      therapeutic phases as the ALLIC-BFM 2002 protocol prescribed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The modification includes:

        1. In the induction phase, the agent of dexamethasone 6 mg/m2 is used instead of prednisone
           after prednisone prophase.

        2. The phase &quot;CAM&quot; is 2 weeks for SR patients and 4 weeks for IR and HR
           patients,respectively.

        3. Both the SR and IR treatments involve the protocol mM /M (8 weeks) in the phase of
           consolidation. However, the folinic acid rescue starts at 36 hours instead of 42 hours.
           The type of HR enters the block treatment the same with the BFM protocol.

        4. There is not randomized study in delayed intensification. The GD-2008 ALL protocol uses
           the same protocol II with the BFM study.

        5. The randomized study focus on the phase of maintenance. The maintenance A is the same
           with the BFM protocol, while the maintenance B consists of 6mp/MTX and VCR/
           dexamethasone. The cycle is 8 weeks: VCR at d1, Dexamethasone at d2 to d7, 6mp from d8
           to d56, and MTX at d9,d16, d23, d30, d37,d44,d51.

        6. The GD-2008 ALL protocol for HR patients use the re-blocks and protocol II phases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The improvement of safety in the treatment protocol</measure>
    <time_frame>Two months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Protocol A (MM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Protocol B (MM/VD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6-mercaptopurine, Methotrexate</intervention_name>
    <description>6-mercaptopurine p.o. qd
Methotrexate p.o. qw</description>
    <arm_group_label>Protocol A (MM)</arm_group_label>
    <other_name>For SR and IR patients (Group one)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone</intervention_name>
    <description>(1)6-mercaptopurine p.o. qd x 7w Methotrexate p.o. qd x 7w
(2)Vincristine qw x 1w Dexamethasone p.o. qd x 7d
Go to (1) and (2)</description>
    <arm_group_label>Protocol B (MM/VD)</arm_group_label>
    <other_name>For SR and IR patients (Group two)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytologically proven acute lymphoblastic leukemia (ALL)

          -  No relapse of a previously unrecognized ALL

          -  Patients must meet one of the following risk criteria:

          -  Standard-risk (SR) group meeting all of the following criteria:

          -  Blasts &lt; 1,000/μL in peripheral blood (PB) on day 8

          -  Aged 1 to &lt; 6 years

          -  Initial WBC &lt; 20,000/μL

          -  M1 (5%) or M2 (≥ 5% to &lt; 25%) blasts in bone marrow on day 15;

          -  M1 marrow on day 33.

          -  Intermediate-risk (IR) group meeting all of the following criteria:

               -  Aged &lt; 1 or ≥ 6 years and/or WBC ≥ 20,000/μL

               -  Blasts &lt; 1,000/μL in PB on day 8

               -  M1 or M2 marrow on day 15

               -  M3 (≥ 25%) marrow on day 15 OR meets SR criteria but M3 marrow on day 15 and *M1
                  marrow on day 33.

          -  High-risk (HR) group meeting ≥ 1 of the following criteria:

               -  Meets IR criteria and M3 marrow on day 15 (not SR and M3 on day 15)

               -  Blasts ≥ 1,000/μL in PB on day 8

               -  M2 or M3 marrow on day 33

               -  Translocation t(9;22) [BCR/ABL+] (Philadelphia chromosome-positive) or t(4;11)
                  [MLL/AF4+].

        Exclusion Criteria:

          -  No Down syndrome

          -  No other major disease that prohibits study treatment (e.g., severe congenital heart
             disease)

          -  Not requiring significant therapy modification owing to study therapy associated
             complications

          -  No complications due to other interventions

          -  No one with missing data that are needed for the differential diagnosis, or for
             selection of the proper therapy arm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianpei Fang, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Second Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xuequn Luo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jianliang Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaofei Sun</last_name>
    <role>Principal Investigator</role>
    <affiliation>The cancer hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xuedong Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang hospital of Nanfang Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liming Tu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dongbo Lai, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangzhou children's hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Changgang Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenzhen Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liyang Liu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huizhou People's Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shaoliang Huang, M.D.</last_name>
    <phone>+8620-81332003</phone>
    <email>luhong.xu@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The second affiliated hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianpei Fang, M.D.</last_name>
      <phone>+8620-81332003</phone>
      <email>jpfang2005@163.com</email>
    </contact>
    <investigator>
      <last_name>Jianpei Fang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2009</study_first_submitted>
  <study_first_submitted_qc>February 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2009</study_first_posted>
  <last_update_submitted>March 5, 2010</last_update_submitted>
  <last_update_submitted_qc>March 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jianpei Fang,MD</name_title>
    <organization>Sun Yat-sen University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

